Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, JJ3-603, Cleveland, OH, 44195, USA.
Center for Outcomes Research & Evaluation, Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Qual Life Res. 2019 Jun;28(6):1585-1594. doi: 10.1007/s11136-019-02130-y. Epub 2019 Feb 13.
Assessment of outcomes from a proxy is often substituted for the patient's self-report when the patient is unable or unwilling to report their status. Research has indicated that proxies over-report symptoms on the patient's behalf. This study aimed to quantify the extent of proxy-introduced bias on the Patient-Reported Outcomes Measurement Information System Global Health (PROMIS GH) scale for mental (GMH) and physical (GPH) scores.
This retrospective cohort study included incident stroke patients seen in a cerebrovascular clinic who completed PROMIS GH between 10/12/15 and 6/6/18. Differential item functioning (DIF) evaluated measurement invariance of patient versus proxy responses. DIF impact was assessed by comparing the initial score to the DIF-adjusted score. Subgroup analyses evaluated DIF within strata of stroke severity, measured by modified Rankin Scale (≤ 1, 2, 3+), and time since stroke (≤ 30, 31-90, > 90 days).
Of 1351 stroke patients (age 60.5 ± 14.9, 45.1% female), proxy help completing PROMIS GH was required by 406 patients (30.1%). Proxies indicated significantly worse response to all items. No items for GMH or GPH were identified as having meaningful DIF. In subgroup analyses, no DIF was found by severity or 31-90 days post-stroke. In patients within 30 and > 90 days of stroke, DIF was detected for 2 items. Accounting for DIF had negligible effects on scores.
Our findings revealed the overestimation of symptoms by proxies is a real difference and not the result of measurement non-invariance. PROMIS GH items do not perform differently or have spuriously inflated severity estimates when administered to proxies instead of patients.
当患者无法或不愿报告自己的状况时,通常会由代理人代替患者进行结果评估。研究表明,代理人会代表患者过度报告症状。本研究旨在量化代理人在代表患者报告时对患者报告结局测量信息系统全球健康量表(PROMIS GH)心理(GMH)和生理(GPH)评分产生的偏差程度。
本回顾性队列研究纳入了在脑血管病门诊就诊的新发脑卒中患者,这些患者在 2015 年 10 月 12 日至 2018 年 6 月 6 日之间完成了 PROMIS GH 量表的评估。差异项目功能(DIF)评估了患者和代理人反应的测量不变性。通过比较初始评分和 DIF 调整后的评分来评估 DIF 影响。亚组分析评估了 DIF 在卒中严重程度(采用改良 Rankin 量表进行评估,≤1、2、3+)和卒中后时间(≤30、31-90、>90 天)分层内的情况。
在 1351 例脑卒中患者(年龄 60.5±14.9 岁,45.1%为女性)中,有 406 例(30.1%)患者需要代理人帮助完成 PROMIS GH。代理人在所有项目上的报告均显著较差。GMH 或 GPH 没有项目被确定为具有有意义的 DIF。在亚组分析中,严重程度或卒中后 31-90 天内未发现 DIF。在卒中后 30 天和>90 天的患者中,有 2 项检测到 DIF。考虑到 DIF,对评分的影响可忽略不计。
我们的研究结果表明,代理人过度报告症状是一种真实的差异,而不是测量不变性的结果。当将 PROMIS GH 量表施测于代理人而不是患者时,其项目不会表现出不同或产生夸大的严重程度估计。